Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

NCT04155710 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: IOV-2001
DRUG: Low dose IL-2
DRUG: High dose IL-2
DRUG: IL-2

Sponsor

Iovance Biotherapeutics, Inc.